Connect with us

News Wire

Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure

– These findings were observed in a Phase 3 clinical trial conducted by Glenmark Pharmaceuticals and has been published by the globally reputed, peer reviewed International Journal of Infectious Diseases

MUMBAI, India, Nov. 23, 2020 /PRNewswire/ — The oral antiviral medication Favipiravir, that prevents the replication phase of the virus life-cycle, leads to significant improvement in clinical cure in patients with mild to moderate COVID-19. These findings were observed in a randomized, controlled Phase 3 clinical study conducted by Glenmark Pharmaceuticals, and the results are now published online in The International Journal of Infectious Diseases (IJID). The IJID is a globally reputed, peer-reviewed, pubmed indexed, open access journal published monthly by the International Society for Infectious Diseases, USA. The published findings will also appear in the print edition of the journal in the coming weeks.

PRNE_Glenmark_Logo

The publication on the study titled “Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19:  A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial” was authored by Dr. Zarir .F. Udwadia and other co-authors .

The link to the article is mentioned below

https://authors.elsevier.com/sd/article/S1201-9712(20)32453-X

https://www.sciencedirect.com/science/article/pii/S120197122032453X 

The Phase 3 study with antiviral drug Favipiravir, brand name FabiFlu®, was conducted in 150 patients as part of a randomised, open label, multicenter, Phase 3 study. The study aimed to evaluate the efficacy and safety of Favipiravir plus standard supportive care (Favipiravir treatment arm), versus standard supportive care alone (control arm), in mild to moderate patients, randomized within a 48 hour window of testing RT-PCR positive for COVID-19.

Favipiravir was found to provide multiple treatment benefits, demonstrated by faster time to clinical cure, and significantly delayed the need for supportive oxygen therapy. Additionally, patients of confirmed COVID-19 with moderate symptoms were discharged from hospital earlier than those patients that did not receive Favipiravir, with the median time to clinical cure reduced by 2.5 days compared with the control group.

Dr Zarir F. Udwadia. MD, FRCP, FCCP, Breach Candy Hospital, Mumbai, commented “Every claim for the efficacy of a new drug in COVID-19 must be backed by evidence from a clinical trial. Glenmark has done just that with Favipiravir. Their well-designed trial in 150 patients showed Favipiravir resulted in a significantly improved time to clinical cure and rapid viral clearance. Based on this I would consider the use of this anti-viral drug in symptomatic patients with mild to moderate COVID-19. I eagerly await the results of similar trials presently being conducted in Boston and at Stanford.” 

Since it was first pronounced a pandemic by the WHO in March, COVID-19 has continued to impact the lives of millions of people globally. As of date, over 50 mn. cases have been reported, with over 1 mn. deaths attributed to this disease. The virus has reportedly spread to all around the world and territories across the globe. Most disease cases are mild to moderate, with symptoms including fever, cough and breathlessness. In severe cases, COVID-19 can cause pneumonia, severe acute respiratory syndrome, kidney failure and death.

Favipiravir is an antiviral medication that works by inhibiting a viral enzyme called RdRP (RNA dependent RNA polymerase), thereby halting the virus’s replication cycle. This helps control the multiplication of the virus and prevents its spread in the patient. This mechanism of action of Favipiravir is novel compared to most antivirals that primarily prevent entry and exit of the virus from cells. Several published reports are now available of the drug’s effectiveness against COVID-19.

Mr. Robert Crockart, Chief Commercial Officer Glenmark Pharmaceuticals, said, “From the first reported case of COVID-19, our every effort was to bring a viable, safe and effective treatment option to patients in a timely manner. It is encouraging to see our trial results now published in a reputed global medical journal, which we hope will support other countries in their fight against this disease.”

Patients in the Glenmark clinical trial received Favipiravir tablets 3,600 mg (1,800 mg BID) (Day 1) + 1,600 mg (800 mg BID) (Day 2 or later) for up to maximum of 14 days, along with standard supportive care. Randomization was stratified based on disease severity into mild and moderate. Favipiravir was well tolerated with no serious adverse events (SAEs) or deaths in the Favipiravir treated arm.

The pre-specified primary endpoint, time from randomisation to cessation of oral shedding of the SARS-CoV-2 virus, demonstrated a 2 day earlier virological cure in the Favipiravir treatment group, though not statistically significant. However, significant improvement in time to clinical cure and other secondary end-points suggest Favipiravir may be beneficial in the treatment of mild-to-moderate COVID-19. 

“The study, which was undertaken by Glenmark Pharmaceuticals, at a time when the number of cases for infections were dramatically increasing around the globe, demonstrates Glenmark’s commitment to ensuring all patients have access to affordable medication, to make a positive impact on their quality of life,” said Dr. Monika Tandon, Sr. Vice President & Head – Clinical Development, Global Specialty/Branded Portfolio at Glenmark.

In June 2020, Glenmark received manufacturing and marketing approval from India’s drug regulator for Favipiravir (FabiFlu®), making it the first oral approved medication in India for the treatment of mild to moderate COVID-19. The manufacturing and marketing approval was granted as part of an accelerated approval process, considering the emergency situation of the COVID-19 outbreak in India. The approval’s restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

About The International Journal of Infectious Diseases

The International Journal of Infectious Diseases (IJID) is a peer-reviewed, pubmed indexed, open access journal that publishes original clinical and laboratory-based research, together with reports of clinical trials, reviews, and some case reports dealing with the epidemiology, clinical diagnosis, treatment, and control of infectious diseases with particular emphasis placed on those diseases that are most common in under-resourced countries. IJID is published monthly by the International Society for Infectious Diseases, USA

About Favipiravir

Favipiravir  is an RNA-dependent  RNA  polymerase  (RdRp)  inhibitor approved  for the treatment  of  novel  influenza  viruses  in  Japan  and  China, with approvals for use in the pandemic across several countries in Asia, Latin America, and the Middle East. Reports of in-vitro studies have demonstrated that Favipiravir can have an effective concentration against the SARS-CoV-2 infection within safe therapeutic dose. Additionally, Favipiravir being an oral formulation – and considering that ∼80% of COVID-19 cases are categorized as mild to moderate – is likely to address unmet clinical needs of a sizeable majority of patient population, which can mostly be treated on an outpatient basis.

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). For more information, visit www.glenmarkpharma.com.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as “promising,” “provides treatment benefit,” may reduce,” “suggest,” or similar expressions, or by express or implied discussions regarding potential new indications or labelling for Favipiravir, regarding potential future revenues from Favipiravir, or regarding the long- term impact of a patient’s use of Favipiravir. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Favipiravir to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Favipiravir will be approved for any additional indications or labelling in any market. Nor can there be any guarantee that Favipiravir will achieve any particular levels of revenue in the future. Neither can there be any guarantee regarding the long-term impact of a patient’s use of Favipiravir. In particular, management’s expectations regarding Favipiravir could be affected by, among other things, unexpected clinical trial results, including unexpected NEW clinical data and unexpected additional analysis of existing clinical trial data; unexpected regulatory actions or delays or government regulation generally; the company’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Glenmark Group’s assets and liabilities as recorded in the Group’s consolidated balance sheet, and other risks and factors referred to in Glenmark Pharmaceutical current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Glenmark Pharmaceuticals is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Logo: https://oyefilmy.in/wp-content/uploads/2020/11/recently-published-data-on-favipiravir-as-treatment-for-mild-to-moderate-covid-19-demonstrates-significant-improvement-in-time-to-clinical-cure-1.jpg

Related Topics:
Continue Reading
Advertisement
Click to comment

You must be logged in to post a comment Login

News Wire

“India has the oldest and most profound culture of storytelling. We learnt everything from storytelling – from the code of conduct to our belief system”: Imtiaz Ali at India Global Forum’s NXT25

MUMBAI, India, April 10, 2025 /PRNewswire/ — Storytelling, cinema, and digital content took the spotlight at ‘Making WAVES – the Culture Forum’ hosted during the India Global Forum’s NXT25: Leading the Leap Summit at the Jio World Convention Centre on April 8. The forum brought together some of India’s most iconic voices across entertainment and media to explore the evolving narrative of India emerging as a global powerhouse for content and digital innovation.

In a Fireside Chat titled, ‘Making WAVES – India as a Global Content Hub’, renowned Director and Writer Imtiaz Ali, said: “As a storyteller, I do not have to worry about what everybody likes. The way to find out the code is by finding what I would like. Since I have been in the film industry, I have been told that formula (movie success) is not working. Thank God for that, because if the formula worked, none of us would be here making movies. We (India) have the oldest and most profound culture of storytelling. We learnt everything from storytelling. Everything has been learnt from stories, from the code of conduct to our belief system.”

Continuing the conversation, Monika Shergill, Vice President – Content, Netflix India, highlighted: “The beautiful confluence of creativity and technology has allowed the creators not to be limited to where they are. The biggest enabler of this trend is a resurgence of hyperlocal. Indian audiences are among the most experiential, diverse, curious, and fantastic audiences. As streamers, storytellers, and creators, we must take advantage of this opportunity.”

This was followed by a conversation with Ekta Kapoor, Joint MD, Balaji Telefilms LTD, on the Intersection of Art, Success & Global Influence. She said, “There are different metrics of success for everyone. At Balaji and I, as content providers, believe success comes in three or four ways: getting the economics right, creating impact, and earning recognition.” On a lighter note, when asked about the upcoming remake of her hit TV show, Kyunki Saas Bhi Kabhi Bahu Thi, Kapoor teased the return of actor and politician Smriti Irani, saying: “We are bringing politics into entertainment or a politician.”

Later, in a Fireside Chat on ‘Inspiring Journeys’, noted actress Fatima Sana Shaikh, opened up about the challenges she faced and said: “This industry has no set rules or frameworks; if it has worked for someone, it doesn’t mean it will work for you. Nothing is permanent, not the highs or lows. We cannot get too attached to fame or failure; work is not our identity.”

Talking about her inspiration, Fatima, said: “I enjoy Kangana’s work. She is an incredible actor. She was one of the first ones to come from the outside and do different movies, like Queen & Tanu Weds Manu.”

Co-hosted with the Ministry of Information & Broadcasting, the Culture Forum also served as a precursor to the upcoming World Audio Visual & Entertainment Summit (WAVES). Speaking on the occasion, Achal Malhotra, CEO, WAVES, National Film Development Corporation Ltd., said: “Most of us have started hearing about WAVES very recently but this was envisioned by our Hon’ Prime Minister way back in 2019. We have done a lot of look and see of the other great shows happening around the world. Therefore, we realised that with technology the way we produce content and the way we are seeing content consumption and also content delivery is changing at a pace we really don’t know what’s going to be the next tool that’s going to come.”

Bringing together CEOs, policymakers, global investors, and industry disruptors, NXT25 explores the biggest trends shaping India’s future on the world stage, spotlighting India’s ambitions for the next 25 years and its emergence as a global powerhouse in investment, technology, sustainability, and innovation.

For session highlights and speaker insights, click here

The summit is supported by the UK Government, Government of Maharashtra, and the Commerce Ministry of India. Bloomberg TV is the official international media partner.

About India Global Forum

India Global Forum tells the story of contemporary India. The pace of change and growth India has set itself is an opportunity for the world. IGF is the gateway for businesses and nations to help seize that opportunity. To know more, click here.

Social Media Handles & Hashtag to Follow

Twitter: @IGFUpdates & @manojladwa

LinkedIn: India Global Forum

#IGFMumbai

Photo: https://oyefilmy.com/wp-content/uploads/2025/04/india-has-the-oldest-and-most-profound-culture-of-storytelling-we-learnt-everything-from-storytelling-from-the-code-of-conduct-to-our-belief-system-imtiaz-ali-at-india-global-forums-nxt25-1.jpg

Logo: https://oyefilmy.com/wp-content/uploads/2025/04/india-has-the-oldest-and-most-profound-culture-of-storytelling-we-learnt-everything-from-storytelling-from-the-code-of-conduct-to-our-belief-system-imtiaz-ali-at-india-global-forums-nxt25-2.jpg

 

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/india-has-the-oldest-and-most-profound-culture-of-storytelling-we-learnt-everything-from-storytelling—from-the-code-of-conduct-to-our-belief-system-imtiaz-ali-at-india-global-forums-nxt25-302425498.html

Continue Reading

News Wire

Creddinv Launches ‘The Smart Investor’ App

India’s first app facilitating 100% digital startup investment processes

BENGALURU, India, April 10, 2025 /PRNewswire/ — Creddinv, India’s premier curated startup investment platform, is set to revolutionize the way investors engage with startups through its new ‘Creddinv: The Smart Investor’ app, launching today.

This first-of-its-kind application is designed exclusively for high-net-worth individuals (HNIs), angel investors and venture capitalists looking to seamlessly discover and invest in India’s most promising startups.

Key Features of the Smart Investor App:

  • Curated Startup Listings – Access thoroughly vetted and high-potential startup investment opportunities.
  • Seamless Investment Process – Invest in a few clicks with a secure and intuitive interface.
  • Real-Time Portfolio Tracking – Monitor the investments and stay updated with market insights.
  • Exclusive Investor Community – Network with seasoned investors and industry experts.

The Smart Investor App becomes an exclusive gateway to invest in startups through Creddinv’s Premium Series, as a part of which investors will be assigned a dedicated investment banker to manage their portfolios.

What is Premium Series?

Premium Series is a curated investment experience launched by Creddinv for investors seeking high-potential private equity opportunities in early-stage startups. Unlike pooled investments like AIF Category I, Premium Series allows investors to invest directly on a startup’s cap table via Compulsory Convertible Preference Shares (CCPS)—alongside prominent angel investors and institutional funds.

Each cohort in the Premium Series features a highly selective group of startups across trending sectors like fintech, electric vehicles (EV), SaaS, agri-tech, consumer & FMCG, Robotics and AI. Only 2% of the startups evaluated make it to the final portfolio—ensuring one can only see the best of the best.

“We believe the future of wealth creation lies in startup investments, and with the Smart Investor App, we are empowering investors to be at the forefront of India’s entrepreneurial revolution, by letting them know every step they take,” said Anil Kumar Kar, Director and Co-Founder of Creddinv.

With startup investments emerging as a key asset class in India’s booming private equity landscape, Creddinv’s Smart Investor App is set to democratize access to high-growth opportunities while making startup investments more transparent, efficient and profitable.

“For years, investing in startups has been complex and reserved for a select few. Today, we change that. The Smart Investor App makes it easier than ever to discover, evaluate and invest in the next big thing in the most transparent way possible,” said Nandakishor, Director and Co-Founder of Creddinv.

The app will be available for download on iOS and Android starting April 10, 2025.

Stay tuned for more updates and be among the first to experience the future of startup investing.

About Creddinv

Creddinv Technologies offers a platform where startup founders and investors connect seamlessly for mutual success. Creddinv revolutionises investing by lowering entry barriers, matching investors with diverse investment opportunities. With its upcoming expansion into wealth creation and portfolio management services, Creddinv continues to provide valuable options for a comprehensive, balanced and informed investment journey.

For more information, visit website: https://www.creddinv.in 

For media inquiries, please contact:

Dhivya Abirami

Lead – Content and PR | Creddinv Technologies

media@creddinv.in 

Video: https://www.youtube.com/watch?v=O6MLpT5gbOg

Logo: https://oyefilmy.com/wp-content/uploads/2025/04/creddinv-launches-the-smart-investor-app-1.jpg

 

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/creddinv-launches-the-smart-investor-app-302425422.html

Continue Reading

News Wire

Icons of 2025: Shaping the Future with Innovation and Leadership

Unveiled by Kiteskraft Productions LLP

CHANDIGARH, India, April 9, 2025 /PRNewswire/ — India’s progress is driven by visionary leaders who embrace innovation and transformative leadership. Icons of 2025: Shaping the Future with Innovation and Leadership presented by Kiteskraft Productions LLP, honors exceptional leaders, trailblazers, and changemakers reshaping industries and fostering progress. Their unwavering commitment and groundbreaking contributions are paving the way for a brighter, more dynamic future for India.

Mr. Samir Chandra Pradhan: Mr. Samir Chandra Pradhan is a symbol of unbreakable willpower. He survived three major accidents, proving his ‘never say die’ attitude.

In the first accident, his left thigh femur was completely damaged. A panel of nine doctors at Medical College Jabalpur, MP, performed a 3.5-hour surgery, inserting five steel rods. Following strict medical advice, he began walking with ease after six months.

In the second accident, a heavy truck crashed into his car thrice, sandwiching it between vehicles. His quick reflexes saved him as he ducked under the steering wheel, escaping without injury. Astonishingly, he resumed work the very next day.

His resilience inspires his students and the public. Mr. Pradhan is also proficient in five languages and a skilled sports analyst. His expertise in sports analysis has been featured in newspapers, further solidifying his reputation. Additionally, his remarkable achievements earned him recognition in Forbes India magazine.

Despite challenges, he remains unstoppable, determined to achieve his goals no matter the obstacles in his path.

Dr. Uppuluri Varuna Naga Venkata Arjun: A Trailblazer in Pharmaceutical Innovation.

Dr. Uppuluri Varuna Naga Venkata Arjun is a distinguished researcher and academic, revolutionizing the field of pharmaceutical sciences. With a Ph.D. in Pharmaceutics from VISTAS, he has made groundbreaking contributions to drug delivery systems, hydrogel scaffolds, and regenerative medicine. His expertise extends to advanced formulations, transdermal therapies, and nanotechnology-driven solutions, shaping the future of modern medicine.

Dr. Arjun’s research portfolio is impressive, boasting a cumulative impact factor of 50.6 and multiple patents in cardiovascular diagnostics. His pioneering work in tissue engineering and novel drug formulations goes beyond theoretical exploration, holding the potential to transform global healthcare and pharmaceutical applications.

Beyond research, Dr. Arjun is a dedicated educator, mentoring aspiring scientists and advancing pharmaceutical education. His excellence has earned him prestigious accolades, including the ‘Young Scientist of the Year’ and the ‘Distinguished Alumni Award for Excellence in Academics and Research‘. With an unwavering passion for discovery and innovation, Dr. Arjun is not just a scientist—he is a visionary shaping the future of medicine and therapeutic advancements.

Dr. Varghese Moolan: Visionary Leader in Business & Philanthropy Global Business Pioneer.

Dr. Varghese Moolan, Founder of Moolans Group, has significantly impacted retail, organic farming, and food processing. He launched Vijay Supermarket in Saudi Arabia (1985) and later established House of Spices Factory Ltd., becoming the first Indian to secure a Saudi Investor License.

Philanthropic Initiatives:

Dr. Moolan’s initiatives include: Touch-A-Heart (2014): 303 free pediatric heart surgeries by 2025, Kindle-A-Candle (2012): Supports medical aid, marriages, and livelihoods, Fly-The-Firefly (2014): Scholarships for underprivileged students, Home-Sweet-Home (2011): Built homes for the needy and Disaster Relief: Aid during Kerala floods (2018) and COVID-19. 

Healthcare & Cinema: Moolans Medicare provides affordable healthcare. He also produced Rocketry: The Nambi Effect (2022) and Odu Raja Odu (2018).

Leadership & Recognition: Dr. Moolan is India-Commonwealth Trade Commissioner (2024) and National Chairman, Anti-Corruption Foundation of India. His accolades include the Golden Book Award (2025) and Saudi Business Excellence Award (2014).

Website: www.themoolans.com

YouTube: @VargheseMoolan

Email: varghese@themoolans.com 

Dr. Janhavi Hase Patil: A Trailblazing Entrepreneur and Social Changemaker.

Dr. Janhavi Hase Patil is a visionary entrepreneur who has gained global recognition through innovation, determination, and excellence.

As the Managing Director of Annapurna-24 Facility Management, she has over 15 years of expertise in catering services, ensuring top-tier quality and hygiene. She also directs Innoventect Engineers Pvt. Ltd., leading strategic engineering projects, and heads MJ Banking Finance, specializing in international onion and vegetable trade.

Beyond business, Dr. Janhavi is dedicated to social causes. As Managing Director of Samvardhan Education Welfare Trust and Chairperson of Samvardhanisa Foundation, she actively promotes health, education, and environmental initiatives. For the past four years, she has provided 25,000 meals annually to Shri Khandoba devotees, reflecting her deep commitment to community service.

Her remarkable contributions to both business and society establish her as an inspiring leader, proving that a single determined individual can create a lasting global impact.

Divyesh Mehta is a seasoned taxation consultant with over three decades of experience in tax planning, compliance, and financial advisory. Renowned for his in-depth knowledge and client-focused approach, he has built a strong reputation for delivering dependable tax solutions across diverse sectors.

Reflecting on recent regulatory changes, Mehta emphasizes the challenges Micro, Small, and Medium Enterprises (MSEs) face with the implementation of mandatory e-invoicing under the GST framework. While the system aims to increase transparency and curb tax evasion, its execution has created significant hurdles for smaller businesses. e-invoicing requires generating invoices via a government portal to obtain an Invoice Reference Number (IRN)—a process that is often cumbersome for MSEs in tier-2 and tier-3 cities with limited access to technology and digital literacy.

According to Mehta, the costs of compliance—software upgrades, consultancy, and digital record-keeping—are disproportionately burdensome for smaller firms. Frequent technical glitches and GST portal downtimes further delay invoicing and payments, leading to liquidity issues. He advocates for more robust support systems, simplified procedures, and targeted training to ensure e-invoicing becomes a tool for empowerment rather than an obstacle to growth.

Dr. Awadhesh Patel: Dr. Awadhesh Patel is a distinguished educator, researcher, and director of Samadhan College. Holding a Ph.D. in Education, he specializes in philosophy, education management, and yoga. He has played a pivotal role in curriculum development, mind and memory training, and educational philosophy. As the founder of Gyanbharti Public School in Raipur, he has contributed significantly to academic excellence.

Dr. Patel has served as President of the Private School Management Association, Dist. Bemetara, and has trained thousands of students and teachers across India in advanced memory techniques. His research on education and scientific coexistence has been presented at esteemed platforms, including IIT Delhi and Singapore. Recognized for his contributions, he has received accolades such as the Asia Education Award (2022) and Lodhi Ratna Samman (2023).

Beyond academics, he actively supports social initiatives in skill development, COVID-19 relief, and environmental conservation. Under his leadership, Samadhan College earned an A grade in NAAC accreditation. Committed to qualitative education, he integrates Consciousness development value education based on Madhyasth Darshan principles to enhance learning and community development.

 Dr.Ajay Desai: A Global Leader in Sustainability, Dr. Ajay Desai has made significant contributions to environmental sustainability through pollution reduction, afforestation, and awareness campaigns. With over a decade of experience, he has worked with 2,000+ companies across 30 countries, promoting eco-friendly policies and sustainable practices. A passionate advocate for afforestation, Dr. Desai has led initiatives planting over 500,000 trees worldwide. He has also trained 500,000 individuals, including professionals, students, and municipal officials, focusing on pollution control, energy conservation, and sustainability. In addition to corporate consulting, Dr. Desai conducts global awareness programs on waste management, climate change, and responsible industrial practices. As a Lead Auditor for ISO 14001 and ISO 50001, he helps businesses achieve environmental compliance. Dr. Desai supports Prime Minister Shri Narendra Modi’s global initiatives for environmental protection and a sustainable future. His dedication has earned him accolades, including recognition in the World Book of Records, India Books, Limca Books, Asia Books, and London Book of World Records. He continues to inspire industries and individuals worldwide.

Dr.Jyoti Rajendra Arde: Dr. Jyoti Arde has devoted nearly 33 years to education, shaping young minds. Initially aspiring to be a medical doctor, destiny led her to earn a Doctorate in Education. Coming from a humble background, her parents—despite limited formal education—ensured she studied in the best schools. Her passion for teaching helped her form a strong bond with students, always encouraging them to pursue their dreams.

Her dedication led her to become a Principal in 2006, serving in various institutions. She takes immense pride in her students’ success, cherishing every milestone. Her contributions earned her numerous prestigious awards, including the Ideal Principal Award, Maharashtra Gunijan Puraskar, Global Teachers Award, Shikshak Ratna Sanman Puraskar, Bharat Jyoti Samaj Ratna Pratibha Gaurav Puraskar, Bharat Shiksha Samman, Most Inspiring Woman Swami Vivekananda National Principal’s Award, and Inspiring Woman Educator Award 2025.

She attributes her success to her family’s unwavering support. She believes every principal is a mentor who nurtures students’ uniqueness. Her philosophy is ‘Live to Inspire’, and she humbly credits her achievements to God, expressing gratitude to all who supported her journey.

 Dr. Ghanshyam Thakur: A Legacy of Knowledge, Service, and Excellence From the modest streets of Badnagar to global recognition, Dr. Ghanshyam Thakur’s journey embodies perseverance, intellect, and an unwavering commitment to service. Born on December 24, 1954, in Badnagar, Madhya Pradesh, he overcame humble beginnings to establish himself as a distinguished scholar, astrologer, writer, and banking professional. His career, spanning over five decades, is marked by intellectual pursuit, cultural contributions, and public service.

Dr. Thakur has been honored with 153 prestigious awards, including the Swami Vivekananda Lifetime Achievement Award, Global Ambassador recognition, Doctor of Excellence in Risk Management and Compliance, and the Universal Lifetime Achievement Award. He holds records in the Golden Book of Records, Magic Book of Records, and the Indian Book of Records, with references across Asia, Indo-ASEAN, Indo-Arab, and Asia-Pacific. An acclaimed author, he has published five books on Amazon and has guided four Ph.D. scholars. His biopic, Vishavakash ke Chamakte Surya, highlights his global renown, cementing his legacy in education, literature, and astrology.

Ms. Chandni: Chandni is a dynamic and passionate professional dedicated to making a meaningful impact. An Emerging Entrepreneur, ATD Certified Trainer, HR Executive, Yog Trainer, I/O Psychologist, and Bharatnatyam Classical Dancer, she seamlessly blends expertise across diverse fields. With a strong background in HR recruitment, Chandni leverages her experience to mentor and guide young professionals, helping them navigate their career paths. Beyond the corporate sphere, she is deeply committed to training and counseling, empowering individuals to unlock their full potential. Women’s empowerment is at the core of her mission. She envisions a world where women achieve financial independence, equality, and the freedom to shape their own futures. Recognizing the significance of mental and physical well-being, Chandni actively promotes holistic health. As a dedicated Yog Trainer, she emphasizes the transformative power of yoga in boosting immunity, positivity, and overall wellness. Her purpose is to add value to lives, her mission is to break the stigma around mental health, and her vision is to inspire a healthier, happier society. She welcomes collaboration on this journey toward positivity and well-being.

About Kiteskraft Productions LLP

Kiteskraft Productions LLP, established in 2019, is a premier organizer of National and International Conferences and Award ceremonies across sectors like Education, Business, Healthcare, NGOs, and Entertainment. With a mission to recognize excellence, Kiteskraft honors individuals who drive innovation and outcome-based learning. Certified by ISO and MSME, and registered under MCA, it upholds high standards of quality. Recognized by the Scholar’s Book of World Records, Kiteskraft fosters industry collaboration through impactful events. With a dedicated team and a vision for excellence, Kiteskraft Productions LLP continues to inspire, empower, and shape a brighter future.

Visit www.kiteskraft.com for more.

Photo: https://oyefilmy.com/wp-content/uploads/2025/04/icons-of-2025-shaping-the-future-with-innovation-and-leadership-1.jpg

 

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/icons-of-2025-shaping-the-future-with-innovation-and-leadership-302424285.html

Continue Reading

Trending